Remdesivir potently inhibits carboxylesterase‐2 through covalent modifications: signifying strong drug‐drug interactions

12/28 N/A

Shen et al., Fundamentals of Clinical Pharmacology, doi:10.1111/fcp.12643 (Peer Reviewed)
Remdesivir potently inhibits carboxylesterase‐2 through covalent modifications: signifying strong drug‐drug interactions

Source PDF Share Tweet

Analysis finding that remdesivir at nanomolar concentrations inhibits carboxylesterase‐2 (CES2) through covalent modifications. CES2 is a major drug‐metabolizing enzyme. Authors conclude that caution must be exercised when remdesivir is used along with drugs hydrolyzed by CES2.

Shen et al., 12/28/2020, peer-reviewed, 3 authors.

All 32 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit

Aspirin	Molnupiravir
Bamlanivimab	Nigella Sativa
Bromhexine	Nitazoxanide
Budesonide	Povidone-Iod..
Casirivimab/i..	Probiotics
Colchicine	Proxalutamide
Conv. Plasma	Quercetin
Curcumin	Remdesivir
Favipiravir	Sotrovimab
Fluvoxamine	Vitamin A
Hydroxychloro..	Vitamin C
Iota-carragee..	Vitamin D
Ivermectin	Zinc
Melatonin

Other	Adoption